Statins, or HMG-CoA reductase inhibitors, are recommended as the first line treatment of hyperlipidemia in patients with established CVD as well as in individuals at high risk for cardiovascular diseases including type 2 diabetes, obesity and metabolic syndrome by current clinical practice guidelines [30, 45, 46]. This evidence concerns the gene HMGCR and metabolic syndrome.